UBS AM
PRCT icon

UBS AM’s Procept Biorobotics PRCT Stock Holding History

UBS AM’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
140,580
+3,842
+3% +$96.2K ﹤0.01% 1846
2026
Q1 		$3.42M Buy
136,738
+946
+0.7% +$26.7K ﹤0.01% 1767
2025
Q4 		$4.27M Buy
135,792
+4,359
+3% +$145K ﹤0.01% 1541
2025
Q3 		$4.69M Sell
131,433
-70,018
-35% -$3.2M ﹤0.01% 1398
2025
Q2 		$11.6M Buy
201,451
+48,293
+32% +$2.73M ﹤0.01% 1286
2025
Q1 		$8.92M Buy
153,158
+13,767
+10% +$940K ﹤0.01% 1280
2024
Q4 		$11.2M Buy
139,391
+22,931
+20% +$1.96M ﹤0.01% 1196
2024
Q3 		$9.33M Buy
116,460
+3,083
+3% +$219K ﹤0.01% 1261
2024
Q2 		$6.93M Buy
113,377
+61,301
+118% +$3.65M ﹤0.01% 1313
2024
Q1 		$2.57M Buy
52,076
+7,853
+18% +$374K ﹤0.01% 1553
2023
Q4 		$1.85M Buy
44,223
+12,086
+38% +$412K ﹤0.01% 1732
2023
Q3 		$1.05M Buy
32,137
+18,552
+137% +$632K ﹤0.01% 1936
2023
Q2 		$386K Hold
13,585
– – ﹤0.01% 2399
2023
Q1 		$386K Buy
13,585
+1,257
+10% +$44.3K ﹤0.01% 2399
2022
Q4 		$512K Buy
+12,328
New +$529K ﹤0.01% 2170

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS AM's PRCT Position: Q2 2026 in Review

UBS AM increased its Procept Biorobotics (PRCT) stake by 2.8% in Q2 2026, buying an estimated $96.2K and bringing the position to 140,580 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

UBS AM first reported a position in PRCT in Q4 2022 and has held it in 15 quarters since. The position peaked at $11.6M in Q2 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • UBS AM held 140,580 shares of Procept Biorobotics worth $3.17M as of Q2 2026.
  • UBS AM bought 3,842 Procept Biorobotics shares in Q2 2026, an estimated $96.2K.
  • Procept Biorobotics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1846 holding.
  • UBS AM first reported a position in Procept Biorobotics in Q4 2022 and has held it in 15 quarters since.
  • UBS AM's Procept Biorobotics position peaked at $11.6M in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.